This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Traditionally, cardiothoracic surgeons have repaired or replaced the tricuspid valve during open-heartsurgery and only when absolutely necessary; such surgeries are complex and risky. Catheter-based procedures offer an alternative for patients who are not candidates for open-heartsurgery.
The HighLife technology will be featured at NY Valves annual meeting on Thursday, June 6th at 11am in the session “Innovation at NYV: Transfemoral TMVR - Technology and Clinical Updates” - Room: Innovation & FDA, 504, Level 5, Jacob K. Javits Convention Center, North.
Tricuspid regurgitation (TR) is a common and serious disease for which openheartsurgery and symptomatic pharmacologic treatment are the current standard treatment options. Owing to high mortality risk, access to openheartsurgery is severely restricted and is not considered an option for most patients with TR.
If the LAAO migrates into the left atrium or ventricle, it can lead to acute heartfailure or even death in a person, necessitating urgent surgical intervention. Left atrial appendage occluder (LAAO) dislodgement with embolization is a rare occurrence.
Sorajja added, "With TriClip, physicians can offer patients a therapy option backed by excellent safety and effectiveness to help restore tricuspid native valve performance without subjecting them to high-risk open-heartsurgery that may not be feasible for individuals with TR who are generally older and sicker."
The potential to detect aortic stenosis through our IH technology is an exciting development that brings us a step closer to achieving the MindMics purpose to one day eliminate heartfailure as the leading cause of death globally (similar to what glucose monitoring has done to transform diabetes)." "We
Traditionally, cardiothoracic surgeons have repaired or replaced the tricuspid valve during open-heartsurgery and only when absolutely necessary; such surgeries are complex and risky. Catheter-based procedures offer an alternative for patients who are not candidates for open-heartsurgery.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content